Surgalign Holdings, INC.: management transactions · United States · SEC (Form 4)

About Surgalign Holdings, INC.

Surgalign Holdings, Inc. (ticker: SRGA) is a United States-based medical technology company with a historical focus on spine surgery and, more broadly, on devices and solutions intended to improve standards of care in the operating room. The company is/was listed in the United States on the NYSE/NASDAQ market, and its SEC filings show a business model shaped by specialty medtech, with emphasis on surgical precision, digital health concepts, and surgeon-support technologies. From a historical perspective, Surgalign was formerly known as RTI Surgical Holdings before adopting the Surgalign name as part of a strategic repositioning toward a more focused spine-oriented platform. SEC materials indicate that, in the early 2020s, the company operated from Deerfield, Illinois, with additional facilities in San Diego, California, as well as sites in Poland and Germany. That footprint highlights a U.S.-headquartered company with a meaningful international operating structure. Public filings also show that the business went through major portfolio changes, including asset sales and a significant narrowing of its operating scope. Operationally, Surgalign had developed, manufactured, and marketed products for spinal procedures, including implants, instrumentation, and related surgical technologies. Its competitive positioning relied on product know-how, commercial distribution capabilities, and an ambition to differentiate through digital health and technology-enabled surgical guidance. In the highly competitive orthopedic and spine device market, the company faced much larger peers with broader product ranges, deeper R&D budgets, and more established surgeon and hospital relationships. That made scale, innovation cadence, and channel execution critical variables. For investors, SRGA should be viewed as a small U.S. medtech case with a transformation-heavy profile rather than a stable, diversified healthcare platform. The most material recent developments documented in public SEC sources include restructuring of the operating perimeter and transactions involving certain assets and subsidiaries, which materially changed the company’s business composition. As a result, the investment case has been shaped less by classic organic growth metrics and more by corporate actions, liquidity considerations, governance signals, and the implications of portfolio simplification. For French-, Belgian-, and Swiss-based investors, the key takeaway is that Surgalign is best analyzed through a special-situations lens: corporate restructuring, insider activity, and SEC disclosures matter at least as much as traditional revenue or margin commentary. In short, SRGA is a U.S. listed medtech name on the NYSE/NASDAQ ecosystem, with a legacy in spine and surgical technology and a recent history marked by strategic repositioning, international operations, and material business changes.